Citations

Showing 10 of 107861 citations.

Autoantibody Profiles and Neurological Correlations of Thymoma
Vernino, Steven , Lennon, Vanda A. , Vernino, Steven

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 10 | Issue: 21 | Pages: 7270-7275

10.1158/1078-0432.ccr-04-0735 | PMID 15534101 Get It

Abstract Purpose: Determine muscle and neuronal autoantibody frequencies in patients with thymoma, with and without paraneoplastic neurological accompaniments. Experimental Design: Analysis of IgG autoantibodies in stored serum collected between 1985 and 2003 from 201 patients with histologically diagnosed thymoma (including six with thymic carcinoma). Contemporary assays quantitated antibodies reactive with muscle and neuronal cation channels, muscle sarcomeric proteins and neuronal cytoplasmic, and nuclear proteins. Results: Neurological diagnoses included myasthenia gravis (MG), myositis, encephalitis, neuromuscular hyperexcitability, autonomic neuropathy, and subacute hearing loss, a previously unrecognized accompaniment of thymoma. Muscle acetylcholine receptor (AChR) binding antibodies were found in all patients with a diagnosis of MG. Muscle autoantibodies (AChR-binding, AChR-modulating, or striational) were also found in 59% of patients without any neurological disorder. One or more neuronal autoantibodies were found in 41% of patients without any neurological disorder, 43% of patients with MG only, and 78% of patients with other neurological disorders. Neuronal autoantibody specificities were, in descending order of frequency, as follows: glutamic acid decarboxylase, voltage-gated potassium channel, collapsin response-mediator protein-5, ganglionic AChR, and antineuronal nuclear antibody-type 1 (ANNA-1). Conclusions: Neuronal autoantibodies complement skeletal muscle autoantibodies as serological markers of thymoma in patients with and without clinical evidence of a neurological disorder. The high prevalence of glutamic acid decarboxylase autoantibody, not previously considered a paraneoplastic marker, justifies its consideration as a marker of thymoma-related neurological autoimmunity. Serological evaluation of a patient’s profile of neuronal and muscle autoantibodies may aid in preoperative identification of an indeterminate mediastinal mass.
Antiangiogenic Properties of Gold Nanoparticles
Basu, Sujit , Nagy, Janice A. , Atala, Anthony , Söker, Shay , Mukherjee, Priyabrata , Bhattacharya, Resham , Wang, Ping , Wang, Ling , Mukhopadhyay, Debabrata

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 9 | Pages: 3530-3534

10.1158/1078-0432.ccr-04-2482 | PMID 15867256 Get It

Abstract Here, we report an intrinsic property of gold nanoparticles (nanogold): they can interact selectively with heparin-binding glycoproteins and inhibit their activity. Gold nanoparticles specifically bound vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-165 and basic fibroblast growth factor, two endothelial cell mitogens and mediators of angiogenesis resulting in inhibition of endothelial/fibroblast cell proliferation in vitro and VEGF-induced permeability as well as angiogenesis in vivo. In contrast, nanogold did not inhibit VEGF-121 or epidermal growth factor, two non–heparin-binding growth factors, mediated cell proliferation. Gold nanoparticles significantly inhibited VEGF receptor-2 phosphorylation, intracellular calcium release, and migration and RhoA activation in vitro. These results report for the first time a novel property of gold nanoparticles to bind heparin-binding proteins and thereby inhibit their subsequent signaling events.
A Phase I Trial of the Novel Farnesyl Protein Transferase Inhibitor, BMS-214662, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Cancer
Dy, Grace K. , Bruzek, Laura M., Croghan, Gary A., Mandrekar, Sumithra J. , Erlichman, Charles , Peethambaram, Prema P. , Pitot, Henry C., Hanson, Lorelei J., Furth, Alfred, Cheng, Shinta , Martell, Robert E., Adjei, Alex A. , Reid, Joel M. , Kaufmann, Scott H.

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 5 | Pages: 1877-1883

10.1158/1078-0432.ccr-04-1769 | PMID 15756013 Get It

Abstract Purpose: This phase I study was conducted to determine the toxicities, pharmacokinetics, and pharmacodynamics of BMS-214662, a farnesyl transferase inhibitor, in combination with paclitaxel and carboplatin, in patients with advanced solid tumors. Experimental Design: Patients with solid tumors received one of six escalating dose levels of BMS-214662 infused over 1 hour given following paclitaxel and carboplatin on the first day of a 21-day cycle. Toxicities were graded by the National Cancer Institute common toxicity criteria and recorded as maximum grade per patient for each treatment cycle. Inhibition of farnesyl transferase activity in peripheral blood mononuclear cells (PBMCs) was evaluated. Accumulation of unfarnesylated HDJ-2 in PBMCs of patients was evaluated as a marker of farnesyl transferase inhibition by BMS-214662. Results: Thirty patients received 141 cycles of treatment through six dose levels. Dose-limiting toxicities were neutropenia, thrombocytopenia, nausea, and vomiting. There was no pharmacokinetic interaction between BMS-214662 and paclitaxel. The maximum tolerated dose was established as BMS-214662 (160 mg/m2), paclitaxel (225 mg/m2) and carboplatin (area under the curve = 6 on day 1), every 21 days. Inhibition of HDJ-2 farnesylation in PBMCs of patients was shown. One measurable partial response was observed in a patient with taxane-resistant esophageal cancer. There was partial regression of evaluable disease in two other patients (endometrial and ovarian cancer). Stable disease (> 4 cycles) occurred in eight other patients. Conclusions: The combination of BMS-214662 with paclitaxel and carboplatin was well tolerated, with broad activity in solid tumors. There was no correlation between dose level and accumulation of unfarnesylated HDJ-2 in PBMCs nor tumor response.
Macrophage Internalization of Fungal β-Glucans Is Not Necessary for Initiation of Related Inflammatory Responses
McCann, Frances V., Carmona, Eva M. , Puri, Vishwajeet , Pagano, Richard E., Limper, Andrew H. , Carmona, Eva M

Mayo Clinic

Infection and Immunity | September 21, 2005 | Volume: 73 | Issue: 10 | Pages: 6340-6349

10.1128/iai.73.10.6340-6349.2005 | PMID 16177305 Get It

ABSTRACT Cell wall β-glucans are highly conserved structural components of fungi that potently trigger inflammatory responses in an infected host. Identification of molecular mechanisms responsible for internalization and signaling of fungal β-glucans should enhance our understanding of innate immune responses to fungi. In this study, we demonstrated that internalization of fungal β-glucan particles requires actin polymerization but not participation of components of caveolar uptake mechanisms. Using fluorescence microscopy, we observed that uptake of 5-([4,6-dichlorotriazin-2-yl] amino)-fluorescein hydrochloride-Celite complex-labeled Saccharomyces cerevisiae β-glucan by RAW macrophages was substantially reduced in the presence of cytochalasin D, which antagonizes actin-mediated internalization pathways, but not by treatment with nystatin, which blocks caveolar uptake. Interestingly, β-glucan-induced NF-κB translocation, which is necessary for inflammatory activation, and tumor necrosis factor alpha production were both normal in the presence of cytochalasin D, despite defective internalization of β-glucan particles following actin disruption. Dectin-1, a major β-glucan receptor on macrophages, colocalized to phagocytic cups on macrophages and exhibited tyrosine phosphorylation after challenge with β-glucan particles. Dectin-1 localization and other membrane markers were not affected by treatment with cytochalasin D. Furthermore, dectin-1 receptors rather than Toll-like receptor 2 receptors were shown to be necessary for both efficient internalization of β-glucan particles and cytokine release in response to the fungal cell wall component.
Ulnar Lengthening and Radial Recession Procedures for Kienböck’s Disease
Trail, Ian A., Linscheid, Ronald L., Quenzer, Delwin E., SCHERER, P. A.

Mayo Clinic

Journal of Hand Surgery | September 21, 2005 | Volume: 21 | Issue: 2 | Pages: 169-171

10.1016/s0266-7681(96)80092-1 | PMID 8732395 Get It

Twenty patients with Kienböck’s disease who had undergone a joint levelling procedure, were reviewed at a mean of 11 years following surgery. Clinical and radiological evaluation revealed good long-term results with all patients complaining of less pain than before surgery and with statistically significant increases in range of motion and grip strength. Radiologically a significant number of patients were found still to have lunate fractures and fragmentation. In addition, 13 patients have developed new bone formation in the lunate fossa, and 12 show osteoarthritic changes, particularly at the radioscaphoid interface. Radial shortening was felt to be superior to ulnar lengthening in that there were fewer problems with bone union.
The Capitohamate Ligaments
Ritt, Marco J.P.F. , Berger, Richard A. , An, Kai‐Nan , Bishop, Allen T.

Mayo Clinic

Journal of Hand Surgery | September 21, 2005 | Volume: 21 | Issue: 4 | Pages: 451-454

10.1016/s0266-7681(96)80044-1 | PMID 8856532 Get It

The physical attributes of the three capitohamate interosseous ligaments were tested in a computer-controlled multi-axis testing machine using 12 human cadaver specimens. After an intact test run, selected ligaments were cut in random sequence and the test repeated. The remaining ligaments were tested to failure with servohydrolic stress at 5 mm/second. In the intact joint complex, the average dorsopalmar rotational displacement was approximately 9° in each direction. Under the load limit, the dorsopalmar translational displacement averaged 0.9 mm and 0.5 mm respectively, proximal–distal translational displacement averaged 0.8 mm and 0.4 mm respectively, and distractional displacement averaged 0.3 mm. Based on the sequential sectioning it was found that the dorsal ligament provided 76% (SD 14) of the rotational resistance with palmar rotation of the capitate and 44% (SD 19) of translational constraint with palmar translation of the capitate. The deep ligament provided 51% (SD 15) of the rotational resistance with dorsal rotation of the capitate and 63% (SD 24) of translational resistance with dorsal translation of the capitate. With proximal—distal translation, the dorsal ligament was the most important constraint in each direction. In resisting distraction, each of the three ligaments was equally effective. Failure testing showed the deep ligament was strongest at 289 N, followed by the palmar at 171 N and the dorsal at 133 N.
Flexor Tendon-Pulley Interaction afterTendon Repair
Coert, J. Henk , Uchiyama, Shigeharu , Amadio, Peter C. , Berglund, L. J., AN, NK

Mayo Clinic

Journal of Hand Surgery | September 21, 2005 | Volume: 20 | Issue: 5 | Pages: 573-577

10.1016/s0266-7681(05)80113-5 | PMID 8543858 Get It

Ten normal ring fingers from ten donors were used to determine the effect of flexor tendon repair on the gliding resistance between the tendon and the A2 pulley. Gliding resistance was measured for the intact FDP tendon and for the same tendon after it was cut transversely and repaired with a 4/0 Ticron core suture and a 6/0 running epitendinous nylon suture. After repair, the gliding pattern of the tendon through the A2 pulley changed significantly. The resistance and the friction coefficient were approximately doubled ( P<0.005).
The First Carpal Tunnel Release?
Amadio, Peter C.

Mayo Clinic

Journal of Hand Surgery | September 21, 2005 | Volume: 20 | Issue: 1 | Pages: 40-41

10.1016/s0266-7681(05)80013-0 | PMID 7759932 Get It

Correspondence is presented recording an operation for release of the carpal tunnel performed in 1924, together with a biographical note on the surgeon, Herbert Galloway.
Correlation between Isoniazid Resistance and Superoxide Reactivity in Mycobacterium tuberculosis KatG
Ghiladi, Reza A. , Medzihradszky, Katalin F. , Rusnak, Frank, Montellano, Paul R. Ortiz de

Mayo Clinic

Journal of the American Chemical Society | September 21, 2005 | Volume: 127 | Issue: 38 | Pages: 13428-13442

10.1021/ja054366t | PMID 16173777 Get It

Symposium on Androgen Action in Prostate Cancer
Tindall, Donald J., Horne, Frances McFarland, Hruszkewycz, Andrew M., Mohla, Suresh, Shuman, Marc, Wang, Zhou , Kantoff, Philip W. , Kantoff, Philip W

Mayo Clinic

Cancer Research | September 20, 2005 | Volume: 64 | Issue: 19 | Pages: 7178-7180

10.1158/0008-5472.can-04-1752 | PMID 15466216 Get It